Zixun Yan - Shanghai Institute of Hematology, Shanghai Jiao Tong University

基本信息

浏览量：32

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 33 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen,Li Wang,Pengpeng Xu,Shu Cheng,Wei Tang, Wen Wu,Mengmeng Ji,Zhong Zheng,Zixun Yan,Lingshuang Sheng,Yige Shen,Weili Zhao

Bloodno. Supplement 1 (2024): 6553-6553

引用0浏览0引用

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Lingshuang Sheng,Zixun Yan,Li Wang, Wen Wu,Yilun Zhang,Rong Shen,Weiguo Cao, Lei Li,Sheng Chen,Xufeng Jiang,Hongmei Yi,Qi Song,Shu Cheng,Pengpeng Xu,Xuanming Yang, Yuxiang Zhu, Xikang Xu, Fuzhe Wang,Jianyong Li,Wei Li Zhao

Bloodno. Supplement 1 (2024): 4822-4822

引用0浏览0引用

18F-FDG PET/CT Metrics-Based Stratification of Large B-cell Lymphoma Receiving CAR-T Cell Therapy: Immunosuppressive Tumor Microenvironment As a Negative Prognostic Indicator in Patients with High Tumor Burden

Ling-Shuang Sheng,Rong Shen,Zi-Xun Yan, Chao Wang, Xin Zheng,Yi-Lun Zhang, Hao-Xu Yang,Wen Wu,Peng-Peng Xu,Shu Cheng,Emmanuel Bachy,Pierre Sesques,Nicolas Jacquet-Francillon,Xu-Feng Jiang,Wei-Li Zhao,Li Wang

Biomarker researchno. 1 (2024): 104-104

引用0浏览0WOS引用

Cholesterol Efflux from C1QB-expressing Macrophages is Associated with Resistance to Chimeric Antigen Receptor T Cell Therapy in Primary Refractory Diffuse Large B Cell Lymphoma

Zi-Xun Yan, Yan Dong,Niu Qiao,Yi-Lun Zhang,Wen Wu,Yue Zhu,Li Wang,Shu Cheng,Peng-Peng Xu,Zi-Song Zhou,Ling-Shuang Sheng,Wei-Li Zhao

Nature Communications（2024）

引用2浏览0WOSNATURE引用

A Phase 1 Study of LY007, a Novel Anti-Cd20 CAR-T Cell Therapy in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Zixun Yan,Lingshuang Sheng,Li Wang,Wen Wu,Yilun Zhang,Rong Shen,Weiguo Cao, Lei Li, Sheng Chen,Xufeng Jiang,Hongmei Yi,Qi Song,Shu Cheng,Peng-Peng Xu,Jianyong Li,Weili Zhao

Journal of Clinical Oncologyno. 16_suppl (2024): 7027-7027

引用0浏览0引用

Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan, Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

crossref（2023）

引用0浏览0引用

Table S3 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan, Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

crossref（2023）

引用0浏览0引用

Figure S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan, Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

crossref（2023）

引用0浏览0引用

Table S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi‐Xun Yan, Li, Wen Wang,Bin-Shen OuYang, Cheng Shi, Li Wang,Pengpeng Xu,Muharrem Müftüoğlu, Ming Hao, Yang Shao‐Horn,Muchen Zhang, Zhong Zheng,James Li, Wei‐Li Zhao

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn